{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:46:38Z","timestamp":1780757198973,"version":"3.54.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Extrahepatic cholangiocarcinoma (ECC) is an uncommon and devastating malignancy that mainly consists of adenocarcinoma. Adenosquamous carcinoma is a rare histologic type and accounts for 2\u20135% of ECC. It reports that 3.6\u20138.5% of ECC patients carry Her-2 amplification. A 45-year-old woman was admitted to our hospital because of jaundice. Abdominal computerized tomography (CT) suggested extrahepatic biliary tract mass. The patient received surgery and pathological examination confirmed adenosquamous carcinoma. Fluorescence in Situ Hybridization (FISH) and Next-generation sequencing showed the tumor had Her-2 amplification. One month after the operation, CT demonstrated distant lymph nodes metastases (cT3N1M1, stage IV). The patient received gemcitabine and cisplatin combined with targeted therapy of trastuzumab. After three cycles of treatment, the evaluation of response was stable disease (SD). The progression-free survival of 1st line treatment (PFS1) reached 5 months with five cycles of treatment. After progression, the patient received three cycles of albumin-bound paclitaxel combined with S-1 and trastuzumab and concurrent chemoradiotherapy (S-1) because of serious backache. Now, the disease is stable, and the PFS of 2nd line treatment (PFS2) has reached 7 months.<\/jats:p>","DOI":"10.3389\/fonc.2021.538328","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T08:43:52Z","timestamp":1614242632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification"],"prefix":"10.3389","volume":"11","author":[{"given":"Ye","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3881.2013.10.02","article-title":"Cholangiocarcinoma: increasing burden of classifications","volume":"2","author":"Cardinale","year":"2013","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67530-7","article-title":"Cholangiocarcinoma","volume":"366","author":"Khan","year":"2005","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/978-1-4419-6082-5","volume-title":"Molecular Genetics of Liver Neoplasia","author":"Wang","year":"2011"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14992020802286202","article-title":"Adenosquamous Carcinoma of Extrahepatic Bile Duct: Clinicopathologic Study of 12 Cases","volume":"1","author":"Hong","year":"2008","journal-title":"Int J Clin Exp"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920715)70:2<415::aid-cncr2820700208>3.0.co;2","article-title":"A cholangiocellular carcinoma nude mouse strain showing histologic alteration from adenocarcinoma to squamous cell carcinoma","volume":"70","author":"Lemura","year":"1992","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000495936","article-title":"Adenosquamous Carcinoma of the Choledochus","volume":"12","author":"Uehara","year":"2018","journal-title":"Case Rep Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, Resectability, and Outcome in 225 Patients with Hilar Cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"B8","first-page":"28","article-title":"Advances in the Management of Biliary Tract Cancers","volume":"11","author":"Ciombor","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu162","article-title":"Second-line chemotherapy in advanced biliary cancer: a systematic review","volume":"25","author":"Lamarca","year":"2014","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2017.06.001","article-title":"Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma","volume":"49","author":"Jung","year":"2017","journal-title":"Pathology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/path.1779","article-title":"Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers","volume":"206","author":"Nakazawa","year":"2005","journal-title":"J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i32.4047","article-title":"High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT\/p70S6K","volume":"16","author":"Treekitkarnmongkol","year":"2010","journal-title":"World J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Pignochino","year":"2010","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11157","article-title":"Therapeutic implication of HER2 in advanced biliary tract cancer","volume":"7","author":"Nam","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.14701\/ahbps.2019.23.4.403","article-title":"Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection","volume":"23","author":"Prieto","year":"2019","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41698-019-0091-4","article-title":"Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma","volume":"3","author":"Yarlagadda","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B18","unstructured":"LiuYB\n          Molecularly target therapy with GEMOX in advanced or recurrent extrahepatic cholangiocarcinoma or gallbladder carcinoma"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S144850","article-title":"Adenosquamous carcinoma of the bile duct: a population-based study","volume":"10","author":"Qin","year":"2018","journal-title":"Cancer Manage Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-004-1520-9","article-title":"Adenosquamous carcinoma of the extrahepatic biliary tract: clinicopathological analysis of Japanese cases of this uncommon disease","volume":"40","author":"Okabayashi","year":"2005","journal-title":"J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","article-title":"Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype","volume":"7","author":"Shui","year":"2014","journal-title":"Int J Clin Exp"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.538328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T13:48:49Z","timestamp":1615211329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.538328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":22,"alternative-id":["10.3389\/fonc.2021.538328"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.538328","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"article-number":"538328"}}